New insights into immunotherapy strategies for treating autoimmune diabetes

dc.contributor.authorCabello Olmo, Miriam
dc.contributor.authorAraña Ciordia, Miriam
dc.contributor.authorRadichev, Ilian
dc.contributor.authorSmith, Paul
dc.contributor.authorHuarte, Eduardo
dc.contributor.authorBarajas Vélez, Miguel Ángel
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.contributor.funderGobierno de Navarra / Nafarroako Gobernuaes
dc.date.accessioned2020-03-06T10:04:32Z
dc.date.available2020-03-06T10:04:32Z
dc.date.issued2019
dc.description.abstractType 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destruction have been extensively investigated. The strategies based on immunotherapies have recently been incorporated into a panel of existing treatments for T1D, in order to block T-cell responses against beta cell antigens that are very common during the onset and development of T1D. However, a complete preservation of beta cell mass as well as insulin independency is still elusive. As a result, there is no existing T1D targeted immunotherapy able to replace standard insulin administration. Presently, a number of novel therapy strategies are pursuing the goals of beta cell protection and normoglycemia. In the present review we explore the current state of immunotherapy in T1D by highlighting the most important studies in this field, and envision novel strategies that could be used to treat T1D in the future.en
dc.description.sponsorshipMiriam Cabello-Olmo was granted by the Industrial PhD program (Navarre Government) (Ref 001114082016000011).en
dc.format.extent26 p.
dc.format.mimetypeapplication/pdfen
dc.identifier.doi10.3390/ijms20194789
dc.identifier.issn1422-0067
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/36405
dc.language.isoengen
dc.publisherMDPIen
dc.relation.ispartofInternational Journal of Molecular Sciences, 2019, 20 (19), 4789en
dc.relation.publisherversionhttps://doi.org/10.3390/ijms20194789
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectDiabetesen
dc.subjectAutoimmunityen
dc.subjectInsulinen
dc.subjectImmunotherapy and clinical trialsen
dc.titleNew insights into immunotherapy strategies for treating autoimmune diabetesen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublication2ae3056b-d2bc-46e8-a90e-5239801ad4c9
relation.isAuthorOfPublication57a9f97c-8c1d-48aa-99d3-8bd229eaad87
relation.isAuthorOfPublication2e998efa-ca5a-491e-9e7f-a8fbbd0094ce
relation.isAuthorOfPublication.latestForDiscovery2ae3056b-d2bc-46e8-a90e-5239801ad4c9

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019100043_Cabello_NewInsights.pdf
Size:
735.12 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: